Efficacy of buspirone in the treatment of opioid withdrawal

Journal of Clinical Psychopharmacology

Volumn 25, Issue 3, 2005, Pages 230-236

  Buydens Branchey, Laure ^a   Branchey, Marc ^a   Reel Brander, Christine ^a  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; DIAMORPHINE; METHADONE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEROIN DEPENDENCE; HUMAN; METHADONE TREATMENT; NEUROTRANSMISSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SEROTONINERGIC SYSTEM; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; WITHDRAWAL SYNDROME;

ADULT; ANALYSIS OF VARIANCE; BUSPIRONE; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 18844392627     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000162804.38829.97     Document Type: Article

References (31)

1. Charney DS, Sternberg DE, Kleber HD, et al. The clinical use of clonidine in abrupt withdrawal from methadone. Effects on blood pressure and specific signs and symptoms. Arch Gen Psychiatry. 1981;38:1273-1277.
2. Jasinski DR, Johnson RE, Kocher TR. Clonidine in morphine withdrawal: differential effects on signs and symptoms. Arch Gen Psychiatry. 1985;42:1063-1066.
3. Gowing L, Ali R, White J. Buprenorphine for the management of opioid withdrawal [Cochrane Review] The Cochrane Library, Issue 1. Chichester, UK: Wiley; 2004.
4. Cervo L, Rochat C, Romandini S, et al. Evidence of a preferential role of brain serotonin in the mechanisms leading to naloxone-precipitated compulsive jumping in morphine-dependent rats. Psychopharmacology. 1981;74:271-274.
5. Neal BS, Sparber SB. Mianserin attenuates naloxone-precipitated withdrawal signs in rats acutely or chronically dependent upon morphine. J Pharmacol Exp Ther. 1986;236:157-165.
6. Akaoka H, Aston-Jones G. Indirect serotonergic agonists attenuate neuronal opiate withdrawal. Neuroscience. 1993;54:561-565.
7. Akaoka H, Aston-Jones G. Opiate withdrawal-induced hyperactivity of locus coeruleus neurons is substantially mediated by augmented excitatory amino acid in put. J Neurosci. 1991;11:3830-3839.
8. Aston-Jones G, Akaoka H, Charlety P, et al. Serotonin selectively attenuates glutamate-evoked activation of noradrenergic locus coeruleus neurons. J Neurosci. 1991;11:760-769.
9. Ahtee L. Chronic morphine administration decreases 5-hydroxytryptamine and 5-hydroxyindoleacetic acid content in the brain of rats. Med Biol. 1980;58:38-44.
10. Tao R, Ma Z, Auerbach SB. Alteration in regulation of serotonin release in rat dorsal raphe nucleus after prolonged exposure to morphine. J Pharmacol Exp Ther. 1998;286:481-488.
11. Gelenberg AJ. Buspirone: seven-year update. J Clin Psychiatry. 1994;55:222-229.
12. Aceto MD, Bowman ER. Suppression of opiate withdrawal and cocaine hyperarousal syndromes by buspirone. Arzneimittelforschung/Drug Res. 1993;43:942-945.
13. Rose JS, Branchey M, Wallach L, et al. Effects of buspirone in withdrawal from opiates. Am J Addict. 2003;12:253-259.
14. Handelsman L, Cochrane KJ, Aronson M, et al. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13:293-308.
15. 1A receptors. Biol Psychiatry. 1985;20:971-979.
16. Eison MS. The new generation of serotonergic anxiolytics. Possible clinical roles. Psychopathology. 1989;22(suppl 1):13-20.
17. Vandermaelen CP, Matheson KG, Wilderman RC, et al. Inhibition of serotonergic dorsal raphe neurons by systemic and iontopheric administration of buspirone, a non-benzodiazepine anxiolytic drug. Eur J Pharmacol. 1986;129:123-130.
18. Peroutka SJ. 5-Hydroxytryptamine receptor subtypes: molecular, biochemical and physiological characterizations. Trends Neurosci. 1988;11:496-500.
19. Cadieux RJ. Azapirones: an alternative to benzodiazepines for anxiety. Am Fam Physician. 1996;53:2349-2354.
20. Robinson DS, Rickels K, Feighner J, et al. Clinical effects of the 5 HT1A partial agonists in depression: A composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol. 1990;10:67S-76S.
21. New JS. The discovery and development of buspirone. A new approach to the treatment of anxiety. Med Res Rev. 1990;101:283-326.
22. Sussman N. The uses of buspirone in psychiatry. J Clin Psychiatry Monogr. 1994;12:3-19.
23. Piercey MF, Smith MW, Lum-Ragan JT. Excitation of noradrenergic cell firing by 5 hydroxytryptamine1A agonists correlates with dopamine antagonist properties. J Pharmacol Exp Ther. 1994;268:1297-1303.
24. Cole JO, Orzack MH, Beake B, et al. Assessment of the abuse liability of buspirone in recreational sedative users. J Clin Psychiatry. 1982;43:69-75.
25. Griffith JD, Jasinski DR, Casten GP, et al. Investigation of the abuse liability of buspirone in alcohol-dependent patients. Am J Med. 1986;80(suppl 3B):30-35.
26. Murphy SM, Owen R, Tyrer P. Comparative assessment of efficacy and withdrawal symptoms after 6 and 12 weeks' treatment with diazepam or buspirone. Br J Psychiatry. 1989;154:520-534.
27. Feigner JP, Cohn JB. Analysis of individual symptoms in generalized anxiety - a pooled, multi study, double-blind evaluation of buspirone. Neuropsychobiology. 1989;21:124-130.
28. Newton RE, Marunycz JD, Alderdice MT, et al. Review of the side-effects profile of buspirone. Am J Med. 1986;80:17-21.
29. Moskowitz H, Smiley A. Efficacy of chronically administered buspirone and diazepam on driving-related skills performance. J Clin Psychiatry. 1982;43:45-55.
30. Smiley A, Moskowitz H. Effects of long-term administration of buspirone and diazepam on driver steering control. Am J Med. 1988;80(suppl 3B):22-29.
31. Schuckit MA. Alcohol and drug interactions with antianxiety medications. Am J Med. 1987;82(suppl 5A):27-33.